14th November 2019 – HIV
Diagnostics Market is anticipated to reach USD 4.48 billion by 2022.
The human immunodeficiency virus (HIV) leads to Acquired Immuno Deficiency
Syndrome (AIDS). HIV attacks the immune system; thereby making one vulnerable
to hoards of diseases. The factors that propel the growth of the HIV
Diagnostics industry include growing number of blood transfusions and blood
donations, prevalence of HIV/AIDS worldwide, assistance offered by
point-of-care instruments & kits, and growing consciousness about HIV/AIDS
and rising administration initiatives.
On the other hand, there are factors
that may hamper the growth of the market including absence of acceptable
testing labs, and restrictions of laboratory-based testing. HIV Diagnostics
Market is anticipated to grow at a significant CAGR of 9.5% in the upcoming
period as the scope, product types, and its applications are increasing across
the globe.
HIV Diagnostics industry may be explored
by Product type, end user, test type, and geography. The market may be explored
by product type as Instruments, Software and Services, Consumables, Kits,
Assay, and Reagents, and the other Consumables. The “Consumables” segment led
the market in 2016 and is anticipated to maintain its dominance by 2025 due to
rising occurrence of HIV/AIDS, and growing enterprises from governments to
fight HIV/AIDS.
Get
a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/hiv-diagnostics-market/request-sample
The HIV Diagnostics Market could be
explored based on end users as Hospitals, Diagnostics Laboratories, Home care
settings, Blood banks, and Others (Gene bank, cell bank, pharma companies, and
Biotechnology). The “Diagnostic Laboratories” segment led the market in 2016
and is anticipated to maintain its dominance by 2022 owing to technological
developments of diagnostics laboratories, and high investment, and increasing
consciousness of HIV/AIDS.
The market may be analyzed by test type
as Tests for Viral Identification, Antibody Test, Viral Load Tests, Tests for
Early Infant Diagnosis, and CD4 Tests. The “Antibody Tests” segment led the HIV
Diagnostics industry in 2016 and is anticipated to maintain its dominance by
2022. The factors that attribute to the growth of market include consciousness
about HIV, growing technological developments in HIV diagnosis.
North America accounted for the major
share of the HIV Diagnostics Market Size in 2017 and will continue to lead in
the forecast period. The factors that could be attributed to the growth include
increasing awareness about HIV, high occurrence and prevalence of HIV/AIDS, and
rising administration initiatives and growing blood donations.
Some of the key players that fuel the
growth of the HIV Diagnostics industry comprise Abbott Healthcare, Alere Inc.,
Brsitol-Myers Squibb, Abbvie Inc., Gilead Sciences, Janssen Therapeutics, Merck
& Co. Inc, BD Biosciences, bioMerieux, VIIV Healthcare, Beckman Coulter,
Sysmex, Partec, Qiagen, Apogee Flow Systems, Zyomyx Inc., Roche Diagnostics,
Mylan Inc., Siemens Healthcare, and PointCare Technologies Inc. The leading
companies are taking up partnerships, mergers and acquisitions, and joint
ventures in order to boost the inorganic growth of the industry.
Get
in touch
At Million Insights, we work with the
aim to reach the highest levels of customer satisfaction. Our representatives
strive to understand diverse client requirements and cater to the same with the
most innovative and functional solutions.
For
More Information, Visit @ https://www.millioninsights.com
No comments:
Post a Comment